Background: The combination DTaP-IPV/Hib vaccine was licensed in the United States in 2008 for children ages 6 weeks through 4 years with doses administered at 2, 4, 6, and 15-18 months of age. The aim of this study was to assess the safety of DTaP-IPV/Hib vaccine routinely administered as part of clinical care to infants at Kaiser Permanente Northern California. Methods: This was an observational, retrospective study that included all 2-month-old infants vaccinated with either DTaP-IPV/Hib or another DTaP-containing vaccine. We monitored all subjects for non-elective hospitalizations, emergency department visits and selected outpatient outcomes (seizures, Guillain-Barré Syndrome, encephalopathy, encephalitis, alteration of consciousness, meningitis, hypersensitivity reactions, immune thrombocytopenic purpura, hemolytic anemia, type 1 diabetes, and Kawasaki disease) beginning with their first dose through 6 months after a 4th dose or until 24 months of age. We calculated incidence rate ratios (IRRs) in the primary analysis by comparing rates of outcomes during the post-vaccination risk interval with rates during a comparison interval more remote from vaccination. Secondary analyses compared outcomes after DTaP-IPV/Hib with those after other DTaP-containing vaccines. We reviewed the medical records of selected outcomes. Results: From October 1, 2008 through July 31, 2010, 14,042 subjects received a first dose of DTaP-IPV/ Hib, 13,194 received 2 doses, 12,548 received 3 doses and 6702 received 4 doses. Overall, there were 166 comparisons with significantly elevated IRRs and 165 comparisons with significantly reduced IRRs. Medical record review of outcomes with significantly elevated IRRs in both the primary and secondary analyses did not suggest any relationship with DTaP-IPV/Hib. Conclusions: This study did not detect any safety concerns following DTaP-IPV/Hib and provides reassurance that DTaP-IPV/Hib administered as part of routine care was not associated with unexpected safety risks.
Introduction
Combination vaccines offer a practical solution to the increasing complexity of childhood immunization by simplifying implementation, increasing compliance with recommended immunization schedules, increasing acceptance among healthcare providers and parents, reducing the number of vaccine injections and avoiding extra clinic visits, decreasing fear and pain among infants and toddlers, reducing costs associated with stocking and administering each of the individual vaccines, and facilitating the inclusion of new vaccines in immunization programs. The Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics, and the American Academy of Family Physicians recommend and generally prefer combination vaccines to be used as indicated for the child's age [1] .
The combination diphtheria, tetanus, pertussis, poliovirus types 1-3, and Haemophilus influenzae type b vaccine (DTaP-IPV/Hib; Pentacel Ò , Sanofi Pasteur, Swiftwater, PA) was licensed in the United States in 2008 for children 6 weeks through 4 years of age for use as a 4-dose schedule at 2, 4, 6, and 15-18 months of age [2] . over 64 million doses having been distributed (including over 48 million doses in the US). Pre-licensure clinical trials evaluating DTaP-IPV/Hib demonstrated comparable safety and immunogenicity with separate administration of its component vaccines [3] . Following DTaP-IPV/Hib licensure in the US, we conducted the current signal detection study to evaluate the safety of DTaP-IPV/Hib administered routinely as part of clinical care to infants and toddlers.
Methods

Study population
This Phase 4, retrospective, observational study was performed as a post-licensure commitment to the US Food and Drug Administration. The study was conducted at Kaiser Permanente Northern California (KPNC), an integrated healthcare organization that provides comprehensive medical care to approximately 3.3 million members. KPNC has an approximate birth cohort of 35,000 per year. KPNC maintains databases that capture all medical care received by its members, including but not limited to all inpatient, Emergency Department (ED), and outpatient clinic visits; immunizations; and pharmacy and radiology data. We identified mortality data through state death reports and KPNC medical records.
We included all 2-month-old infants who received a DTaP-containing vaccine as part of routine clinical care in KPNC. This study began October 1, 2008 (the date DTaP-IPV/Hib was introduced in KPNC) and accrued new infants until the first occurrence of either the end of the first study year or 10,000 infants who had received DTaP-IPV/Hib vaccine for the primary series. We followed all infants from the time of the first dose of a DTaPcontaining vaccine through either 6 months after their 4th dose, or until 24 months of age, whichever occurred first.
Outcomes
We monitored vaccinees for all non-elective hospitalizations, and all outcomes in ED setting. Only a limited number of preselected outpatient outcomes recorded during the 30 day postvaccination risk interval were evaluated. The pre-specified outpatient outcomes were seizures (post-vaccination days 0-3 only), Guillain-Barré Syndrome, encephalopathy, encephalitis, alteration of consciousness (other than secondary to another diagnosis), meningitis, hypersensitivity reactions (urticaria, angioedema, or anaphylaxis; post-vaccination days 0-3 only), new-onset autoimmune disease (immune thrombocytopenic purpura [ITP], hemolytic anemia), type 1 diabetes, and Kawasaki disease. We identified all outcomes by ICD-9 diagnostic codes. We monitored for all deaths during the study period using state records.
Chart reviews
We conducted medical record chart review for all pre-specified outpatient outcomes listed above in order to verify the diagnosis and determine the timing of onset. We also conducted chart reviews for outcomes for which the analyses revealed an elevated incidence rate ratio (IRR) and for which either biologic plausibility or a temporal relationship suggested a possible relationship to vaccination. Study investigators assessed relatedness and biologic plausibility through electronic medical record review.
Subject grouping
We categorized all vaccinees into 6 groups according to the brand of DTaP received ( , GlaxoSmithKline) for doses 1-3, and either Pediarix or Infanrix vaccine for Dose 4; Group 6 children received a mixture of DTaP brands for the 4 doses (i.e., more than one brand of DTaP) or the brand was unknown for at least one dose.
Statistical analyses
We used the multi-level Healthcare Cost and Utilization Project (HCUP) coding structure to organize outcomes hierarchically into meaningful groups by body systems and condition categories [4] . We calculated IRRs and 95% Confidence Intervals (CIs) for all outcomes. Although an IRR was not calculable when there were no events during the control interval, a lower bound for the IRR was calculable and was considered to be significantly elevated when it was greater than one. We also performed additional review to further characterize outcomes for which analyses indicated a potential increased risk. No adjustments were made for multiple comparisons.
Risk-interval cohort analyses
The primary analysis was a risk-interval analysis in Group 1 children. This method has been utilized in similar post-licensure vaccine safety studies [5] [6] [7] [8] [9] [10] [11] and compares rates of events during days 0-30 post-vaccination (risk interval) with rates of events during days 31-60 post-vaccination (comparison interval). As described above, we calculated IRRs and 95% Confidence Intervals (CIs) for all outcomes. For seizures and hypersensitivity reactions, we assessed events during the 0-3 day risk interval compared with those during the 31-60 day comparison interval. For analyses of all doses combined, we aggregated the day 0-30 (or day 0-3 as appropriate) risk intervals following each dose. For all analyses, we censored person-time at the time of subsequent vaccine dose administered prior to post-vaccination day 61.
Between-cohort analyses
Secondary analyses compared outcomes between groups (''between-cohort analyses"). We compared incidence of outcomes during the 0-30 day risk interval in Group 1 with those during the 0-30 day risk interval in the other groups. Due to small numbers of subjects in Groups 2-4, our main secondary analysis focused on 
Supplemental analyses
By-dose analyses: We performed by-dose analyses comparing outcomes within 30 days after each dose of DTaP-IPV/Hib for both the risk-interval and between-cohort analyses. All subjects were considered ''pure" at Dose 1 but subjects could ''crossover" at a successive dose, at which point they would join Group 6 for that dose and all subsequent doses. For example, an infant who received DTaP-IPV/Hib vaccine for Dose 1 followed by DTaP-HBV-IPV vaccine for Dose 2 would be included in Group 1 for the dose-1 by-dose analysis, Group 6 for the dose-2 by-dose analysis, and Group 6 in the all-doses-combined analysis. This study was approved by the KPNC Institutional Review Board. The ClinicalTrials.gov Identifier is NCT00804284.
Results
Subject accrual occurred between October 1, 2008 and July 31, 2010. In Group 1, there were a total of 14,042 subjects who received 1 dose of DTaP-IPV/Hib vaccine, 13,194 who received 2 doses, 12,548 who received 3 doses, and 6702 who received 4 doses. The largest comparison group, Group 5 DTaP-HBV-IPV recipients, had a total of 46,634 subjects who received 1 dose of DTaP-HBV-IPV, 43,893 who received 2 doses, 41,367 who received 3 doses and 28,481 who received 4 doses. Approximately 29% of study subjects received a different Dose 4 than of the DTaP series they started. Demographic and racial characteristics were generally similar between the groups, although those in Groups 2 and 4 tended to be older at age of first dose and Group 5 had a smaller percentage of subjects who were white race (supplemental table online). There were no subjects who met pre-specified criteria for categorization into Group 3 because neither Tripedia nor TriHIBit vaccine were used at KPNC during the study period. Overall, the seasonality of vaccination was similar across the groups and across all doses.
Receipt of concomitant vaccines was generally similar between the combination DTaP vaccine groups (Groups 1 and 5 for Doses 1-3); however, due to the greater variability in vaccines administered at 12-15 months, no calculation for Dose 4 was performed (data for concomitant vaccine percentages not shown).
ED and hospital analyses
Including all inpatient, ED, and outpatient outcomes among all analyses (i.e., Doses 1-4 individually, first 3, and 4 doses combined), we performed a total of 58,640 IRR calculations, of which 166 were significantly elevated and 165 were significantly decreased (these 331 calculations represented 100 HCUP categories). When we analyzed only specific doses (i.e., doses 1-4 individually), 70 IRRs were significantly elevated and 67 were significantly decreased.
In the primary Group 1 risk-interval analysis, including all settings and all doses of DTaP-IPV/Hib (either individual doses or all doses combined), 20 HCUP categories were significantly elevated (Table 2 ) and 12 HCUP categories were significantly decreased (data not shown). Of these, we reviewed the medical records of cases during the risk interval in three HCUP categories: skin and subcutaneous tissue infections; symptoms, signs and ill-defined conditions, and factors influencing health status; and fever of unknown origin. None of the reviews suggested a relationship with DTaP-IPV/Hib (Table 4) .
Secondary analyses compared events 30 days post-vaccination between Group 1 and Group 5 (DTaP-HBV-IPV) and demonstrated comparable ED and hospital outcomes. Analyses of individual doses and all doses combined revealed 32 significantly elevated HCUP categories (Table 3 ) and 20 significantly decreased HCUP categories (data not shown). We reviewed medical records for the following HCUP categories that occurred significantly more often after DTaP-IPV/Hib: respiratory failure, diseases of the genitourinary system, other complications of surgical and medical procedures, poisoning by other medications and drugs, and lymphadenitis (Table 4) . One case of lymphadenitis occurred at the site of a vaccine administered concomitantly with DTaP-IPV/ Hib and was considered potentially related to receipt of the concomitant vaccine. None of the outcomes were considered related to DTaP-IPV/Hib.
Comparing Group 1 with Group 6 (crossover group) yielded similar findings to those seen both in the primary Group 1 and the secondary Group 1 versus Group 5 analyses, with the addition that acute and chronic tonsillitis (HCUP category 8.1.3) was increased after DTaP-IPV/Hib in the hospital setting. Medical record review did not suggest a relationship to DTaP-IPV/Hib (Table 4) .
Pre-specified outcomes
There were no significantly elevated pre-specified outcomes in the outpatient setting after DTaP-IPV/Hib. There were 3 cases of hypersensitivity (urticaria) in 2 subjects that were considered related to DTaP-IPV/Hib, although there were significantly fewer hypersensitivity reactions in Group 1 (N = 2) compared with Group 2 (N = 1; IRR 0.31, 95% CI 0.002-0.927). Four subjects experienced 5 seizures within 72 h after vaccination that were considered related to DTaP-IPV/Hib. There were no cases of Guillain-Barré Syndrome, encephalitis, or meningitis during the 30-day risk interval after DTaP-IPV/Hib in the outpatient setting, and none of the diagnoses of alteration of consciousness or encephalopathy were considered related to DTaP-IPV/Hib. There were no cases of ITP or type 1 diabetes in the outpatient setting during the risk interval after DTaP-IPV/Hib. There was 1 case of hemolytic anemia and 2 cases of Kawasaki disease after DTaP-IPV/Hib; none were considered related to DTaP-IPV/Hib.
Supplemental analyses
Outcomes with significantly elevated IRRs identified in ''by dose" analyses were included in either the primary Group 1 riskinterval analysis ( 
Discussion
In this study, we assessed the safety of DTaP-IPV/Hib vaccine administered to 14,042 infants who received at least one dose, including 6703 who received a complete 4-dose series with the vaccine as part of routine clinical care. We evaluated all ED and hospital visits during the 30 days after vaccination and found 166 HCUP category outcomes with significantly elevated IRRs. Although there were 165 category outcomes with significantly reduced IRRs in ED and hospital visits, these results are not shown because they were mainly used to put outcomes with elevated IRR in context (i.e., to examine the consistency of study findings). After reviewing the medical records of selected outcomes in the context of biological plausibility, consistency of signal, temporal relationship, and signal strength, we identified no unexpected safety signals after DTaP-IPV/Hib vaccination. We further found that the safety of DTaP-IPV/Hib vaccine was comparable with that of DTaP-HBV-IPV vaccine. This study provides reassurance that DTaP-IPV/Hib was not associated with unanticipated safety risks.
All subjects in this study were vaccinated according to routine clinic practice within KPNC, and the majority received either DTaP-IPV/Hib (Group 1) or DTaP-HBV-IPV (Group 5). Subjects in Group 2 and Group 4 also received care at the same KPNC clinics, but their parents or physicians chose to use separate DTaP vaccines instead of the combination vaccines that were routinely administered at KPNC. Subjects in the DTaP-IPV/Hib and DTaP-HBV-IPV groups had comparably high percentages of subjects who received the recommended concomitant vaccines at Doses 1, 2, and 3. Individuals in Groups 2 and 4 were older at first vaccination (average age 4.9 months versus approximately 2 months) and were less likely to receive the recommended concomitant vaccines during the infant series, suggesting that there were a number of important differences between individuals in Groups 1 and 5 versus those in Groups 2 and 4. Since there were far fewer individuals in Groups 2 and 4, and given these differences between groups, we focused our analyses on subjects in Groups 1 and 5.
The findings from this study are similar to those of another study [12] that used group sequential methods to compare 149,337 vaccinees of DTaP-IPV/Hib with both historical recipients of DTaP-containing vaccines as well as current recipients of other DTaP-containing vaccines during the same period. That study did not find increased risk for seizure, meningitis/encephalitis/myeli tis, non-anaphylactic serious allergic reaction, anaphylaxis, Guillain-Barré syndrome, or invasive Hib disease. Unlike the current study, Nelson et al., found a modest decrease in medically attended fever in infants 6 1 year old and an increased risk in medically attended fever in 1-2 year olds. As in our study, Nelson et al., found that the safety profile of DTaP-IPV/Hib was similar to that of concurrent recipients of other DTaP-containing vaccines.
Before licensure in the US, the safety and immunogenicity of DTaP-IPV/Hib vaccine was evaluated in multiple randomized clinical trials in the US and Canada among more than 9500 subjects, of whom over 7000 received this vaccine during the infant series or toddler booster dose. The rates of injection-site and systemic reactions and serious adverse events were similar to those in children vaccinated with separately administered single-entity equivalent vaccines [3, 13, 14] .
In contrast to pre-licensure clinical trials that evaluate vaccine safety among a smaller number of subjects, adverse events with low frequencies of occurrence may escape detection or adequate characterization until the product is used in a larger number of individuals. Further, following licensure, vaccines are routinely used more widely in clinical practice. A particular strength of this study was our ability to introduce DTaP-IPV/Hib vaccine into the KPNC health plan and subsequently follow infants vaccinated as part of routine clinical care. Another strength was our ability to investigate potential safety findings by easily accessing medical records, which allowed for in-depth review of the clinical histories and detail of the course and timing of illness for selected subjects.
Finally, an important strength of this study was the comparison of outcomes after DTaP-IPV/Hib with those following other DTaPcontaining vaccines, particularly DTaP-HBV-IPV; neither the primary nor secondary analyses detected any safety outcomes, which provide support for the conclusion that DTaP-IPV/Hib was not associated with new safety concerns. This study had limitations. Although we reviewed most safety concerns that arose in this study, review of all potential outcome events was not feasible for safety surveillance of this scale. We therefore limited our efforts to investigating outcomes that were both elevated statistically and for which there was some biological plausibility. We were also not able to always differentiate between outcomes which occurred acutely post-vaccination and those which occurred prior to vaccination (i.e., ''history of" diagnoses) without medical record review. However, we believe that our use of differing comparison periods and vaccine groups minimized potential biases that could be associated with such misclassification. Further, the DTaP vaccine type administered was mostly based on clinic preference and it was conceivable that differences in practice between clinics could influence study findings between groups. Finally, this study was not large enough in size to detect rare outcomes. There were two cases of inpatient respiratory failure in the risk interval. The first was admitted 26 days after vaccination due to pneumonia and the second was admitted 9 days after vaccination due to seizure with fever, breathing difficulty, and hernia protrusion. Based on investigator review of each case, neither event was considered to have been related to receipt of DTaP-IPV/Hib, but the latter case may have potentially been related to MMRV Diseases of the genitourinary system (10) 14/30 cases were in the UTI category and were evenly distributed throughout the 30 day risk interval. The timing ranged between day 1 and day 29, with the mean on day 16. The remaining 16 cases were: balanitis/ balanoposthitis (N = 3), hematuria (N = 2), phimosis (N = 2), acquired hydrocele (N = 1), acute pyelonephritis (N = 1), chronic renal insufficiency (N = 1), dysuria (N = 1), penile discharge (N = 1), penis edema (N = 1), proteinuria (N = 1), urinary retention (N = 1), vesicoureteral reflux (N = 1). Based on investigator review of these disparate outcomes, they were not investigated further and were determined to have an unlikely relationship to receipt of DTaP-IPV/Hib Diseases of the urinary system (10.1) 14/23 cases in this group were the same UTI cases described above and these cases led to the elevated risk in this category. The 14 cases were more likely to be seen after the first and second doses: 7 cases after Dose 1, 3 cases after Dose 2, 2 cases after Dose 3, and 2 cases after Dose 4 Skin and subcutaneous tissue infections (12.1) This outcome underwent further investigation because it was elevated in the primary analysis as well as in supplementary analyses (i.e., elevated after any DTaP-IPV/Hib dose when compared with other pure groups combined; data not shown). There were 11 cases in this larger category as follows: cellulitis and abscess of neck (N = 1, day 18), cellulitis and abscess of upper arm and forearm (N = 1, day 11), cellulitis and abscess of buttock (N = 3, between days 13 and 19), cellulitis and abscess of foot except toes (N = 1, day 7), impetigo (N = 1, day 19), pilonidal cyst without mention of abscess (N = 3, between days 16 and 30), and Unspecified local infection of the skin and subcutaneous tissue (N = 1, day 27). Details about location where specified and the timing of these infections did not suggest a relationship to vaccination or the injection site Other complications of surgical and medical procedures (16.10.2.7)
There were two cases in this group. The first was hospitalized 30 days after DTaP-IPV/Hib (and concomitant vaccines) and available records indicate that the infant had a vomiting episode associated with two seizures while overseas. The treating physicians indicated the illness was due to norovirus but without confirmation. The second case was hospitalized 26 days after DTaP-IPV/Hib (and concomitant vaccines). This infant was one of the 8.6.1 Respiratory failure cases described above. This category was not investigated further Poisoning by other medications and drugs (16.11.2)
There were a total of 11 cases combined after the 3rd and 4th doses. Of these, one that was after the 4th dose of DTaP-IPV/Hib was determined by the study investigator (Klein) possibly to be related to receipt of DTaP-IPV/Hib. It consisted of an approximate 3 Â 4 cm flat area of erythema near the injection site that was diagnosed as ''Vaccines adverse reaction". Of the remaining 10 cases, 3 occurred after the 3rd dose and 7 after the 4th dose of DTaP-IPV/Hib. Those after the 3rd dose had the following diagnoses: accidental possible amlodipine ingestion (day 7); possible cigarette ingestion (day 6), and a child who developed a rash after taking amoxicillin for otitis media (day 6). The 7 cases after the 4th dose were related to ingestions or medication reactions: rash after sulfamethoxazole and trimethoprim (day 7), unknown ingestion when found with grandparent's pill container (day 20), ingestion of parent's anti-depressants (day 26), possible ingestion of lisinopril (day 15), onion ingestion (day 30), overdosing of heart medication (day 20), and ingestion of blue fluid from a popped squeeze toy (day 12) Symptoms; signs; and ill-defined conditions and factors influencing health status (17) This is a broad category but most cases involved fever (discussed below under HCUP 17.1.2). The largest two categories of non-fever events were ''Nausea with vomiting" and ''Vomiting alone" of which there were 16 total cases. The range of days was from the day 1 to day 18. The mean days for medical attention were 11 and 6, respectively, or 8.6 when the two categories are combined. Additionally, one sub-category was allergic reactions of which there were four cases, two of which were determined by the investigator to be related to receipt of DTaP-IPV/Hib (both being cases of urticaria beginning on the day of vaccination) Fever of unknown origin (17. 1.2) There were 50 cases that were distributed evenly throughout the 30-day risk interval. There was no apparent relationship with DTaP-IPV/Hib vaccination Lymphadenitis (17. 1.3) There were 3 cases of lymphadenitis, occurring on days 9, 17 and 20 after DTaP-IPV/Hib. One case occurred at the injection site of a different vaccine and was considered as potentially related to the concomitant vaccine. On investigator review, the remaining two cases were considered to be unrelated to any vaccine a Acute and chronic tonsillitis (8.1.3) was not significantly elevated in the primary self-control analysis (Table 2 ) or in the secondary analysis of DTaP-IPV/Hib versus DTaP-HBV-IPV (Table 3 ). This category was significantly elevated in a secondary analysis that compared recipients of DTaP-IPV/Hib with crossover subjects (Group 6).
In conclusion, the safety of DTaP-IPV/Hib was comparable with other DTaP-containing vaccines used in this age group. The study did not detect any safety signals following DTaP-IPV/Hib and provides reassurance that DTaP-IPV/Hib administered as part of routine care is not associated with unexpected safety concerns.
